Thus, this unique in vitro model provides an excellent platform to study the temporal and spatial regulation of postnatal de novo vasculogenesis, as well as attack the lingering limit in developing engineered tissues, that is perfusion.
Our human in vitro model provides the foundation for compound screenings with the goal to restore physiological spastin levels in patient samples and thereby paves the road to discover new treatment strategies for SPG4-related HSPs.
Notably, hPGCLCs evidently represent the earliest stages of the human germ cell lineage, indicating that our in vitro model provides an important opportunity to explore the mechanism of hPGC specification, which is otherwise not possible because E9 E14 postimplantation human embryos are excluded from investigations.
Based on the standpoint that three-dimensional (3D) multicellular spheroid cultures are currently considered to be the in vitro model providing the most realistic simulation of the human tissue environment, they performed a biocompatibility investigation using this type of modelling.
In vitro modeling provides opportunities for more precise control of test variables, more rapid throughput, and more consistency of cell growth, but typically lacks the complexity found in the brain (for example, three-dimensional (3D) ventricular and brain components with fluid flow).
In vitro models provide advantages for studying virulence mechanisms, given the controlled environment and ease of sample collection.
In studies, applying indirect measures of protein turnover, in vitro models provide results that suggests that attenuated energy turnover and loss of muscle mass may be developed at hypoxia exposure due to a decrease in overall protein turnover rate [7] [10].
Moreover, even if the effect measures were the same, different experimental models cannot be considered equally informative and reliable: obviously, human and in vivo models provide a higher level of evidence as compared to animal and in vitro models (provided that each study is equally well designed, performed and analyzed).
Furthermore, in vitro models provided evidence to support the role of cyclin D1b as an oncogene, fostering transformation of primary cells and cooperating with established oncogenes to drive tumor formation in vivo.
Although the in vitro models provide a convenient and renewable platform that cannot be surpassed by clinical specimens, it may not faithfully reflect the behavior of tumor cells in vivo.
Thus, in addition to expected individual patient variations, these data highlight the strong discordance between observations of gene expression in different in vitro models, providing the context in which current oncogenomic studies must be interpreted.
